Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare effects of preoperative and postoperative use of
topical ketorolac tromethamine 0.4% versus placebo in uncomplicated cataract surgery.
Patients scheduled to undergo phacoemulsification will be randomized to receive either
topical prednisolone acetate 1% 4 times daily (QID) plus dextran 70/hypromellose QID (placebo
group) or topical prednisolone 1% QID plus ketorolac tromethamine 0.4% QID (ketorolac group)
for three days preoperatively and four weeks postoperatively. The primary outcome 5 weeks
after surgery will be angiographic cystoid macular edema.